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Abstract: Physical activity status is increasingly recognized as a reliable predictor of mortality and hospitalization in 
patients with chronic obstructive pulmonary disease (COPD). The reduction in physical activity occurs earlier in the 
clinical course of COPD than previously appreciated, possibly arising from breathlessness, reduced exercise tolerance, 
and adoption of a more sedentary lifestyle. To date, no clinical trial has evaluated the impact of pharmacotherapy on both 
lung function and physical activity. We recently designed a study that evaluates the impact of tiotropium (a once-daily 
inhaled anticholinergic) on lung function and physical activity in a maintenance/treatment-naïve Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) Stage II COPD cohort. Previous studies have demonstrated that tiotropium 
improves lung function and exercise tolerance; whether these benefits translate into improvements in physical activity is 
the focus of the current work. Here we describe the rationale and challenges in developing and implementing this study 
and review its unique features and novel design, including: utility of direct activity monitoring in multi-center clinical 
trials; importance of behavioral-modification techniques (including motivational interviewing to improve patient self-
efficacy and adherence for a healthy, more active lifestyle); utility of individualized activity plans that provide an 
integrated approach with pharmacotherapy and behavioral modification to help patients achieve a more active lifestyle. 
Keywords: COPD, physical activity, activity monitor, tiotropium, methodology, study design. 
INTRODUCTION 
  Physical inactivity is associated with poor long-term 
outcomes, including hospitalizations and mortality in chronic 
obstructive pulmonary disease (COPD) [1, 2]. Moreover, 
higher physical activity levels decrease the risk of 
developing cardiovascular and metabolic diseases [3, 4], 
which are important co-morbidities in COPD. Consequently, 
maintaining physical activity is considered an important 
treatment goal for these patients because the potential impact 
for reduction in co-morbidities is especially important in 
early disease [5]. 
  Patients with Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) Stage II COPD are reported to be 
more physically inactive compared with healthy control 
subjects [6-8]. Although improvements in exercise tolerance 
and exertional dyspnea have been convincingly shown in 
moderate COPD, there is only circumstantial evidence that  
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bronchodilator therapy may enhance physical activity levels 
in patients with COPD [9, 10]. First, dynamic hyperinflation 
contributes to exercise-related symptoms in early disease 
[11, 12] and it is related to physical activity levels — daily 
physical activity in patients with COPD is mainly associated 
with dynamic hyperinflation [13]. Dynamic hyperinflation is 
alleviated by bronchodilator therapy [14]. Second, a sub-
analysis of the Understanding Potential Long-term Impacts 
on Lung Function with Tiotropium (UPLIFT
®) trial 
suggested that the long-acting anticholinergic agent, 
tiotropium, could be used successfully as a first-line 
maintenance therapy in COPD to improve quality of life, 
particularly in the domain of physical activity [15]; other 
benefits were enhanced lung function and reduced 
exacerbation rate. The latter may be of particular importance 
as exacerbations lead to long-term reductions in physical 
activity. Lastly, exercise tolerance and symptoms associated 
with physical activity were reported to be improved when 
bronchodilators were administered to patients with GOLD 
Stage II COPD [9, 10]. 
  Another important but poorly studied problem in early 
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COPD patients who are of working age [16]. It may be 
worthwhile to investigate the impact of optimizing 
pharmacotherapy on worker productivity as well. 
  We hypothesized that, if lung function improvement can 
be sustained or even improved early in the disease, this may 
potentially impact on both short- and long-term 
improvements in patient-centered outcomes such as 
symptoms, health-related quality of life (HRQoL) and 
physical activity [17]. To test this hypothesis, we designed a 
multi-center clinical trial to evaluate the impact of 
pharmacologic intervention with the inhaled once-daily 
anticholinergic agent, tiotropium, on lung function and the 
amount of physical activity using an activity monitoring 
device in COPD. Tiotropium significantly improves 
breathlessness, lung function, and exercise tolerance (cycle 
ergometry endurance time) in patients with COPD [9, 10] 
and has been shown to improve treadmill endurance time, 
especially when added to pulmonary rehabilitation [18]. To 
our knowledge, this is the first time physical activity in 
COPD during pharmacologic intervention in a multi-center 
trial has been systematically examined using an activity 
monitoring device. 
  Here we describe the methodology and discuss the 
challenges associated with the implementation of a multi-
center clinical trial assessing lung function and physical 
activity with pharmacologic intervention in patients with 
GOLD Stage II COPD who are not receiving maintenance 
therapy (maintenance naïve). 
METHODS 
Study Objectives 
  The primary objective of this trial (NCT00523991) is to 
assess the efficacy and safety of tiotropium 18 g inhalation 
capsule via HandiHaler
® compared with placebo in subjects 
with moderate COPD (post-bronchodilator forced expiratory 
volume in 1 second [FEV1] 50-80% predicted; GOLD Stage 
II) who have not previously been treated with maintenance 
therapy, i.e. who have only been treated with short-acting -
agonists on an as-needed basis in the 6 months prior to study 
enrollment and who have symptomatic shortness of breath. 
Study Design 
  This is a 24-week, randomized, double-blind, placebo-
controlled, multinational study, involving a target sample 
size of approximately 436 maintenance-naïve patients with 
Stage II COPD (Fig. 1). The primary endpoint is lung 
function improvement as captured by the area under the 
curve (AUC) of FEV1 versus time (FEV1AUC 0-3h). Lung 
function is assessed before (trough) and after administration 
of the study drug and patients are monitored for 3 hours after 
administration. Physical activity is assessed during the week 
prior to each study visit, using a validated activity monitor as 
a secondary endpoint. Additional secondary objectives 
include the effect of tiotropium treatment on other lung 
function variables, patient and physician global evaluations, 
worker productivity as assessed by the Work Productivity 
and Activity Impairment questionnaire [19], and the use of 
rescue medication. Information on COPD exacerbations is 
collected through serious adverse event monitoring. 
 
Study Population 
  Eligible patients have a clinical diagnosis of COPD 
according to GOLD guidelines criteria; post-bronchodilator 
FEV1/forced vital capacity (FVC) <70% [5]; be aged 40-80 
years; men or women; be current or former smoker with a 
smoking history 10 pack years; have a post-bronchodilator 
FEV1 50% and <80% predicted normal value [5, 20, 21]; 
and symptoms of dyspnea when walking on an incline 
(dyspnea grade 2) [22]. Prior to randomization, all patients 
are required to pass an exercise stress test [23, 24], perform 
spirometry satisfactorily, and to demonstrate compliance 
with wearing the activity monitor and using the HandiHaler
® 
device. At screening, after downloading the patients’ activity 
monitor data, a compliance and activity report is generated. 
Compliance with the activity monitor was prospectively 
defined as use 80% of time during waking hours for 
approximately 14 hours/day, 7 days/week. The exact 
definition of compliance with the activity monitor to be used 
in the statistical analysis will be determined after assessment 
of the distribution of the blinded data. 
  Patients are excluded if they: (1) were treated with 
maintenance respiratory medications within the 6 months 
prior to screening; (2) had an upper respiratory tract infection 
or COPD exacerbation in the 6 weeks prior to the screening 
visit or during the screening visit prior to Visit 3; (3) had 
non-pulmonary disease that would limit physical activity 
(e.g. arthritis, amputation); (4) had a history of asthma, 
cystic fibrosis, pulmonary fibrosis, bronchiectasis, 
pulmonary resection or other significant respiratory disorders 
other than COPD; (5) had significant diseases other than 
COPD which, in the opinion of the investigator, may 
influence the results of the study or the patient’s ability to 
participate; (6) contraindication to exercise testing; (7) had 
prior participation (within 2 years) of either cardiac or 
pulmonary rehabilitation. 
Interventions 
  Eligible patients are randomized to receive either 
tiotropium (18 μg) via HandiHaler
® plus as-needed albuterol 
(salbutamol), or placebo via  HandiHaler
®  plus as-needed 
albuterol, and seen at monthly intervals thereafter until study 
completion. Open-label albuterol can be used as rescue 
medication and the number of puffs per day noted in the 
patient diary. There are no restrictions for medications 
prescribed for treatment of exacerbations as long as they are 
used for fewer than 2 cumulative weeks. 
Procedures 
Spirometry 
  Pulmonary function tests are performed at baseline and at 
Weeks 8, 16, and 24 and are in accordance with criteria 
established by the American Thoracic Society and European 
Respiratory Society [25-27]. FEV1 and FVC are assessed at 
several time points: before (trough: 24 hours after the 
previous dose and 10 minutes prior to the next dose) and 
after (30, 60, 120, and 180 minutes) inhalation of the study 
drug. Post-bronchodilator testing is performed at the 
screening visit only for disease staging. 
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Physical Activity Using the Activity Monitor 
  Physical activity and estimated energy expenditure over 
time are determined by the activity monitor. Patients 
undergo two separate 1-week familiarization/training 
sessions for the physical activity monitor (SenseWear
® 
Armband
®; BodyMedia, Pittsburgh, PA, USA). Reminder 
telephone calls prompt the wearing of the physical activity 
monitor for the week prior to each study visit. 
 The  SenseWear
® Armband
® is a lightweight (80 g), 
multi-sensor device worn on the right upper arm (triceps) 
that assesses acceleration in two planes (i.e. bi-axial 
accelerometer), skin temperature, near body temperature, and 
galvanic skin response. Energy expenditure is based on 
algorithms in the software (SenseWear
® 6.1). The device has 
been validated for use in several populations previously, 
including COPD [28, 29], and data comparing COPD with 
age-matched healthy controls are available [4, 7, 15, 29]. 
Patients are instructed to wear the armband for a week and 
for as long as they can during the day, preferably >14 
hours/day, only removing it for personal hygiene (avoiding 
water contact). 
  Compliance with wearing the activity monitor in minutes 
per day is recorded. Analysis of physical activity endpoints 
will be based as Activity Evaluable Set (ACTES) defined as 
subjects who use their armband at least for 4 days a week for 
at least 11 hours per day and have physical activity and 
energy expenditure data available for 12 weeks. Parameters 
of physical activity and energy expenditure (over time, using 
age-appropriate pre-defined activity metabolic equivalent 
[MET]) as determined by the activity monitor include: (1) 
Average time spent per day in: light intensity (1.5-3 METS) 
activity; moderate or higher intensity (3 METS) activity 
[30-33]; (2) healthy lifestyle (defined as 30 minutes of 
activity >3 METS for 70% of eligible days according to 
ACTES) [31]; (3) the average Active Energy Expenditure 
(kcals spent in activities noted above and previously 
expressed as METS per day); (4) the average number of 
steps per day. 
Patient Diary 
  Patients are required to maintain a diary throughout the 
study that includes self-reporting of daily rescue albuterol 
inhalations, information on breathlessness, and the 10-point 
modified BORG scale data for gauging intensity of physical 
activity. 
Behavioral Modification Intervention 
  In order to raise the awareness on the importance of 
adopting a physically active lifestyle, and to facilitate the 
transition towards a more active lifestyle, all patients receive 
behavioral intervention focused on enhancing physical 
activity levels. This intervention, integrated into the clinical 
visits, consists of: (1) a monthly face-to-face 20-minute 
consultation with site personnel who were trained to discuss 
physical activity levels and set goals trying to enhance 
physical activity; (2) an individual activity action plan based 
on the patient’s current physical activity levels, indicating a 
possible and individualized step-up program; and (3) 
provision of educational material in the format of a DVD. 
 
Fig. (1). Study design. The study consists of nine clinic visits (V1-V9) over 28 weeks. There is a 4-week screening period that includes Visit 
1/Week 4 with single-blind placebo run-in at Visit 2/Week 3; and a 24-week double-blind phase that includes Visit 3/Week 0 (baseline), 
Visit 4/Week 4, Visit 5/Week 8, Visit 6/Week 12, Visit 7/Week 16, Visit 8/Week 20 and Visit 9/Week 24 (end of the study). 4    The Open Respiratory Medicine Journal, 2011, Volume 5  Troosters et al. 
  Motivational interviewing principles are applied in face-
to-face meetings with the patient. Motivational interviewing 
is a client-centered, directive method of conversation with 
patients to enhance intrinsic motivation to change behavior 
(in this case physical activity) by exploring and resolving 
ambivalence [34]. The emphasis is on eliciting the person’s 
intrinsic motivation for change. Change is usually 
accomplished incrementally with small steps. 
Activity Plan 
  Every month, all patients receive an individualized 
activity plan based on the previous month’s downloaded 
activity monitor data, coupled with the review of the 
previous month’s activity diaries. At each study visit, the 
data from the activity monitor is downloaded and a report 
generated that formed the basis of the 20- to 30-minute face-
to-face discussion for the individualized activity plan. The 
activity plan is essentially a guided step-up plan towards 
enhanced physical activity based on the patient’s current 
measured activity level (Fig. 2). Using motivational 
interview techniques, trained site staff discuss the current 
physical activity levels with the patient and his/her 
willingness to engage in more physical activities if needed. 
Statistical Methods 
  The sample size estimation was based on the Swedish 
“Mild” results using a conservative estimate of 300 mL for 
the standard deviation of AUC0-3h FEV1 [35]. A sample size 
of 382 patients is required in order to detect a 100-mL 
difference in mean AUC0-3h FEV1 between the tiotropium- 
and placebo-treatment groups at Week 24 with 5% level of 
significance with 90% power using a two-tailed t-test. An 
estimated drop-out rate of 12% was used to determine the 
final target sample size of 436 patients. 
  Efficacy analyses for lung function will be performed on 
each group and will be expressed as an improvement of 
FEV1 AUC0-3h response from baseline to Week 24 (end of 
treatment). Response is defined as the change from baseline 
(Week 0) to 3 hours’ post-dose FEV1 AUC0-3h at the final 
visit (Week 24). AUC is computed using the trapezoidal rule 
and normalized by dividing by 3 hours. All hypotheses will 
be tested using a Type I error rate of 0.05. All statistical tests 
will be performed as two-sided tests. The primary efficacy 
analysis for FEV1  AUC0-3h will be performed using an 
analysis of covariance (ANCOVA) model with terms for 
treatment group and investigator site, and baseline value as 
covariate. All continuous variables will be analyzed by 
ANCOVA models, with terms for treatment group and 
investigator site, and baseline value as covariate. Categorical 
variables will be analyzed by Cochran-Mantel-Hansel tests 
[36, 37] with investigator site as the stratification variable. If 
distributional assumptions for parametric models are 
violated, then non-parametric methods will be used. 
  Data on physical activity and energy expenditure 
endpoints will be collected throughout the duration of the 
study and analyzed using the previously defined ACTES. 
Physical activity and energy expenditure over time in each 
group will be expressed as an improvement of parameter   
 
response from baseline to Week 24 (end of treatment). 
Response is defined as the change from baseline to Week 24. 
Analysis will be conducted using ANCOVA and will be 
adjusted for baseline value and site. 
  The proportion of patients meeting criteria for a healthy 
lifestyle (based on time spent in moderate activity and steps) 
will be calculated and compared.  
  Correlation analyses of activity monitor outputs as 
measured by the time spent per day in all physical activities 
using age appropriate pre-defined activity MET levels at the 
baseline with the Clinical COPD Questionnaire [38] and the 
Chronic Respiratory Disease Questionnaire [39-41], 
respectively, will be conducted as an exploratory analysis. 
DISCUSSION 
  The diagnosis of COPD using spirometry, although 
recommended, usually does not occur until symptoms 
become evident and until late in the course of the disease. 
Consequently, little is known about the treatment strategies 
and potential benefits of maintenance therapy in patients 
with earlier stage disease who are maintenance naïve. The 
challenge in this patient cohort is to relate the impact of 
maintenance therapy on lung function for the short- and 
long-term with enduring patient-centered healthcare benefits. 
The present study addresses this challenge by analyzing the 
effect of tiotropium as first-line maintenance therapy on lung 
function and, secondly, analyzing the impact of tiotropium 
on pulmonary function, physical activity levels, and work 
productivity. Inactivity is directly linked with the long-term 
burden of COPD [42]; therefore, efforts to improve physical 
activity levels early in the disease process may be a first step 
towards reducing the overall burden of morbidity in these 
patients. 
  Recent advances in our understanding of COPD disease 
progression suggest that there are multiple patient outcome 
benefits attendant to treating symptoms of dyspnea and 
declining lung function early in the course of COPD (e.g. 
Stage II) [43]. Interestingly, the subgroup analysis among 
maintenance-naïve patients from the UPLIFT
® study 
demonstrated that tiotropium (in addition to any other 
respiratory medication except anticholinergics) achieved 
significant improvements in lung function, HRQoL 
(including a clinically important difference in St George’s 
Respiratory Questionnaire total score over 4 years), and a 
reduction in the rate of decline of FEV1 (53 mL/year) 
compared with the control group (42 mL/year) [15]. In 
addition, it has recently been shown that dynamic 
hyperinflation significantly impedes activities of daily life 
[44]. Hence, it is reasonable to assume that improving 
dynamic hyperinflation may improve physical activity 
levels. 
  By focusing on GOLD Stage II COPD patients who had 
not yet been treated with maintenance pharmacotherapy, we 
expect to recruit a relatively large proportion of patients with 
an FEV1 >60% predicted normal who were more recently 
diagnosed/symptomatic, current smokers, younger and 
consequently still employed [28, 45] (thereby enabling   
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(Fig. 2) contd….. 
Panel (B) 
 
Fig. (2). Activity plan for (A) all patients and (B) active patients. Panel A – Patients are encouraged to walk or cycle at a “moderate” 
Modified BORG (CR-10) Score for breathlessness (3/10 to 4/10). *Patients whose physical activity exceeds 30 minutes of activity >3 METS 
five days a week, and who want to further increase their physical activity, proceed to Panel B. Panel B – Patients are considered active if they 
exceed 30 minutes of physical activity >3 METS five days a week. *Options for advancing activity level include: 1) increase the time spent 
walking/cycling in increments of 5-10 minutes 5/7 days and/or walking more briskly; 2) gradually increase activity to 6/7 days; or 3) focus 
on lifestyle adjustments (e.g. use stairs instead of elevator). Considerations in Assessing the Impact of Tiotropium in Maintenance Naïve Patients with Moderate COPD  The Open Respiratory Medicine Journal, 2011, Volume 5    7 
exploration of a work productivity outcome) [19], and a 
higher proportion of female patients, reflecting demographic 
changes reported in COPD [46, 47]. 
  Physical activity assessment, reflecting real life, is a new 
patient-centered outcome measure in trials investigating the 
effects of pharmacotherapy in COPD. The selection of 
clinically meaningful outcomes for use in COPD clinical 
trials continues to evolve and expand from the more familiar 
focus on lung function, exacerbations, exercise, mortality, 
and HRQoL, towards more novel, functionally relevant 
patient-centered outcomes such as “free-living” activity. 
Maintaining activity for life in patients with COPD is a goal 
of effective treatment and management [5, 48], which 
impacts the clinical course of COPD by improving exercise 
tolerance, improving quality of life, decreasing 
exacerbations, and prolonging survival [1, 2, 17, 49]. The 
current study is, to our knowledge, the first multi-center 
clinical trial in COPD with pharmacologic intervention to 
assess lung function and objectively monitor activity coupled 
with interventions (behavioral modification and an 
individualized activity plan) aimed to increase/maintain 
activity in a full spectrum of GOLD Stage II maintenance-
naïve COPD patients. Such data will expand our 
understanding of the long-term potential benefits of early 
treatment with maintenance pharmacotherapy in COPD. 
  An anticipated technical challenge in the current study is 
patient compliance with the activity monitor. Recent studies 
have suggested that patients may be insufficiently compliant 
in wearing activity monitors, even in single-center studies, or 
that technical malfunctions will occur [50, 51]. However, a 
recent pilot study that used the same device in a cohort of 
COPD patients demonstrated activity monitor compliance 
rates of >90% at each of the three study sites [7]. This study 
also demonstrated that, consistent with other studies [6, 8], 
the decline in physical activity occurred early in the course 
of the disease (GOLD Stage II) and that patients with COPD 
reduce their physical activity by reducing the intensity of 
activity while maintaining the number of steps. Thus 
monitoring only the number of steps may, therefore, 
overestimate the actual level of energy expenditure as light 
intensity exercise is maintained but moderate intensity 
activity (>3 METS), which is important for health benefits, 
is markedly reduced. Lastly, the pilot study confirmed that 
the physical outcome measures used in the current study are 
reproducible. It is yet unclear what the impact of seasonality 
will be on the present study. Recent data from the UK 
suggest physical activity to be very variable with season 
[52]. Classical physiological measures of exercise tolerance 
may be more stable but may, from a patient’s perspective, be 
less important. 
  A duration of 6 months was selected for the current study 
in order to allow for a gradual change in physical activity 
and for a true behavioral shift. Patients are supported with 
monthly activity and behavioral counseling (using 
motivational interviewing techniques), measurement of 
physical activity, and face-to-face meetings to discuss 
progress, with the aim of encouraging small monthly 
increases in physical activity; this has been successful in 
other clinical settings [53, 54]. 
  Data from the present trial may also help to define the 
importance of integrating several therapeutic interventions 
(activity monitoring, consultation on physical activity, the 
implementation of an activity plan, and pharmacotherapy) in 
the disease management of patients with COPD. A previous 
study has demonstrated success in enhancing exercise 
tolerance by combining pulmonary rehabilitation and 
tiotropium in patients with more severe COPD [18]. The 
present study will define the value of providing regular 
feedback on physical activity levels along with optimal 
pharmacotherapy and whether it suffices in enhancing 
physical activity levels in patients with moderate COPD. 
SUMMARY 
  The current study is, to our knowledge, the first multi-
center clinical trial in COPD with pharmacologic 
intervention that will assess lung function and physical 
activity outcomes, coupled with specific interventions 
(behavioral modification and an individualized activity plan) 
aimed towards increasing/maintaining activity in a full 
spectrum of GOLD Stage II maintenance-naïve COPD 
patients. While tiotropium improves laboratory-based 
exercise performance, the translation into improved physical 
activity outcomes in a large multi-center clinical trial has yet 
to be investigated and is the focus of the current study. The 
study design and methodology implemented here will 
advance our knowledge of the value of early intervention to 
relieve symptoms and improve lung function, and to provide 
further incentive to patients with COPD to be more 
physically active, prevent long-term morbidity and to enjoy a 
healthier lifestyle. 
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ABBREVIATIONS 
ACTES  =  Activity Evaluable Set 
ANCOVA =  Analysis of covariance 
AUC  =  Area under the curve 
CCQ =  Clinical  COPD  Questionnaire   
COPD  =  Chronic obstructive pulmonary disease 
CRQ  =  Chronic Respiratory Questionnaire  
FEV1  =  Forced expiratory volume in 1 second 
FVC  =  Forced vital capacity 
GOLD  = Global Initiative for Chronic Obstructive   
     Lung Disease 
HRQoL  =  Health-related quality of life 
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UPLIFT
®  =  Understanding Potential Long-Term Impacts   
     on Lung Function with Tiotropium 
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